RXi Pharmaceuticals Corporation is a discovery-stage biopharmaceutical company that is engaged in the development and potential commercialization of proprietary therapeutics. It conducts various research studies based on RNA interference for the treatment of human diseases. The company offers the rxRNA compound, which is potent and nuclease resistant. Its products have potential uses in the recovery of several inflammatory diseases, such as rheumatoid arthritis, Crohn s disease, atherosclerosis and diabetes. RXi Pharmaceuticals Corporation s oligonucleotide-based product research is sponsored by the Drug Information Association. It additionally works in collaboration with the University of Massachusetts for the development of orally delivered RNA interference therapeutic technologies.